Brooke Mastrogiacomo
A5071927490- Cancer Genomics and Diagnostics
- Intraperitoneal and Appendiceal Malignancies
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
- Radiomics and Machine Learning in Medical Imaging
- RNA modifications and cancer
- Genetic factors in colorectal cancer
- Colorectal Cancer Treatments and Studies
- Peptidase Inhibition and Analysis
- Biomedical and Engineering Education
- Mechanisms of cancer metastasis
- Bioinformatics and Genomic Networks
- Lung Cancer Research Studies
- Genetics, Bioinformatics, and Biomedical Research
- Ferroptosis and cancer prognosis
- Cancer Mechanisms and Therapy
- Epigenetics and DNA Methylation
- Cancer Cells and Metastasis
- Biochemical Analysis and Sensing Techniques
- Cancer Immunotherapy and Biomarkers
- Innovative Microfluidic and Catalytic Techniques Innovation
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Biotechnology and Related Fields
- Gastric Cancer Management and Outcomes
- Cancer, Stress, Anesthesia, and Immune Response
Memorial Sloan Kettering Cancer Center
2018-2025
Kettering University
2021-2025
Molecular Oncology (United States)
2021-2024
American Association For Cancer Research
2021
Abstract International cancer registries make real-world genomic and clinical data available, but their joint analysis remains a challenge. AACR Project GENIE, an international registry collecting from 19 centers, makes >130,000 patients publicly available through the cBioPortal for Cancer Genomics (https://genie.cbioportal.org). For 25,000 patients, additional longitudinal data, including treatment outcome are being collected by GENIE Biopharma Collaborative using PRISSMM curation...
The digitization of health records and growing availability tumour DNA sequencing provide an opportunity to study the determinants cancer outcomes with unprecedented richness. Patient data are often stored in unstructured text siloed datasets. Here we combine natural language processing annotations1,2 structured medication, patient-reported demographic, registry genomic from 24,950 patients at Memorial Sloan Kettering Cancer Center generate a clinicogenomic, harmonized oncologic real-world...
Real-world data sets that combine clinical and genomic may be subject to left truncation (when potential study participants are not included because they have already passed the milestone of interest at time recruitment). The lapse between diagnosis molecular testing can present analytic challenges threaten validity interpretation survival analyses.Effects ignoring when estimating overall illustrated using from American Association for Cancer Research (AACR) Project Genomics Evidence...
Abstract Purpose: KRAS G12C is the most common mutation in primary lung adenocarcinoma. Phase I clinical trials have demonstrated encouraging activity of KRASG12C inhibitors metastatic setting. We investigated disease-free survival (DFS) and tumor genomic features patients with surgically resected KRASG12C-mutant Experimental Design: Patients who underwent resection stage I–III adenocarcinoma next-generation sequencing (NGS) were evaluated. Exclusion criteria receipt induction therapy,...
<h3>Importance</h3> Contemporary observational cancer research requires associating genomic biomarkers with reproducible end points; overall survival (OS) is a key point, but interpretation can be challenging when multiple lines of therapy and prolonged are common. Progression-free (PFS), time to treatment discontinuation (TTD), next (TTNT) alternative points, their utility as surrogates for OS in real-world clinicogenomic data sets has not been well characterized. <h3>Objective</h3> To...
Abstract Purpose: The first comprehensive analysis of the detailed clinico-genomic landscape breast cancer (BC) cohort American Association for Cancer Research (AACR) Project Genomics Evidence Neoplasia Information Exchange (GENIE) Biopharma Collaborative (BPC). Methods: We analyzed 1, 045 BC patients treated at three GENIE-participating institutions. Breast in GENIE registry aged 18-56 sequencing and with tumor(s) sequenced between 2013 2018 were randomly chosen curation using PRISSMM...
Background: Epidermal growth factor receptor (EGFR) mutations occur in 15-50% of patients worldwide with lung adenocarcinoma (LUAD). While tyrosine kinase inhibitors (TKIs) that directly target activating EGFR prolong the survival these LUAD patients, most tumors inevitably develop acquired resistance to TKI therapy. The second frequent cause such is amplification MET oncogene, which occurs about 20% EGFR-mutated samples resistance. Our prior study showed Vorinostat (VS), a potent HDAC...
Abstract While next-generation sequencing (NGS) is used to guide therapy in patients with metastatic lung adenocarcinoma (LUAD), use of NGS determine pathologic LN metastasis prior surgery has not been assessed. To bridge this knowledge gap, we performed using MSK-IMPACT 426 treatment-naive clinical N2-negative LUAD. A multivariable logistic regression model that considered preoperative and genomic variables was constructed. Most had cN0 disease (85%) pN0, pN1, pN2 rates 80%, 11%, 9%,...
Background Dysgeusia is a common but understudied complication in patients undergoing autologous hematopoietic cell transplantation (auto‐HCT). We assessed the feasibility of using chemical gustometry (CG) to measure dysgeusia and explored its associations with symptom burden, nutrition, chemotherapy pharmacokinetics (PK), oral microbiome. Methods conducted single‐center, prospective study (NCT03276481) multiple myeloma auto‐HCT. CG was performed longitudinally testing five flavors (sweet,...
About 50% of patients with early-stage, surgically resected lung cancer will develop distant metastasis. There remains an unmet need to identify likely recurrence and design innovative therapies decrease this risk. Two primary isoforms BRMS1, v1 v2, are present in humans. Using next-generation sequencing BRMS1 on matched human noncancerous tissue non–small cell (NSCLC) specimens, we identified single-nucleotide polymorphism (SNP) rs1052566 that results A273V mutation BRMS1v2. This SNP is...
Abstract Clinical data storage in unstructured notes and siloed datasets present a major challenge for large-scale cancer informatics. Whether natural language processing (NLP) combined with multimodal integration across can produce mineable resource improve discovery of relationships between tumor genomics clinical phenotypes is unknown. We hypothesized that NLP could automatically annotate pan-cancer corpus 82,464 patients genomic sequencing. To develop algorithms to free-text reports, we...
Abstract Background: Tumor heterogeneity plays a crucial role in disease progression, metastasis and treatment response lung adenocarcinoma (LUAD). Limited availability of multiple molecularly profiled samples from the same patients poses challenge to validate models tumor evolution using real-world data. We investigated genomic changes large cohort with clinically directed DNA sequencing LUAD samples. Methods: analyzed longitudinal data 524 at least two sequenced MSK-IMPACT- targeted panel...
Abstract The digitization of health records and prompt availability tumor DNA sequencing results offer a chance to study the determinants cancer outcomes with unprecedented richness; however, abstraction key attributes from free text presents major limitation large-scale analyses. Using natural language processing (NLP), we derived sites metastasis, prior treatment at outside institutions, programmed death ligand 1 (PD-L1) levels, smoking status patients create richly annotated...